Rezvilutamide with surgery and targeted radiation for early-spread prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if adding the drug rezvilutamide to standard hormone therapy, along with prostate removal surgery and precise radiation to cancer spots, helps men whose prostate cancer has spread to a limited number of places (no more than 10 spots, and not in organs like the liver or lungs).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to 10 or fewer spots (in bones or lymph nodes outside the pelvis) and not to your organs.
- You are about to start or have just started (within the last 4 weeks) hormone therapy that lowers testosterone.
- Your overall health is good enough for surgery and radiation, with no major heart, lung, bleeding, or bone marrow problems.
- You have not had any prior prostate cancer treatment except hormone therapy that started within the last 4 weeks.
- Your kidney, liver, and blood cell counts meet basic safety levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of surgery and radiation to remove as much cancer as possible in men with prostate cancer that has spread to a few spots outside the prostate. It aims to see if this aggressive approach can improve long-term outcomes.
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
This trial tests whether adding a drug called enzalutamide to standard radiation and metastasis-directed therapy improves outcomes for men with recurrent prostate cancer that has spread to a few spots. It's for those whose PSA is rising quickly.
This trial tests whether giving radiotherapy to the prostate and a few cancer spots elsewhere in the body can help control low-spread prostate cancer. It is for people who have not had any previous prostate cancer treatment.
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
Hear when a new Oligometastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.